Opiant Pharmaceuticals - OPNT Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$20.21
▼ -0.02 (-0.10%)

This chart shows the closing price for OPNT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Opiant Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OPNT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OPNT

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Opiant Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $20.21.

This chart shows the closing price for OPNT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 2 contributing investment analysts is to hold stock in Opiant Pharmaceuticals. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/17/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/15/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/14/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/14/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/12/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/10/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/9/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/23/2022Northland SecuritiesDowngradeOutperform ➝ Market PerformLow
11/22/2022Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
3/16/2022Cantor FitzgeraldReiterated RatingOverweightHigh
12/8/2021OppenheimerInitiated CoverageOutperform$42.00Low
7/7/2021Northland SecuritiesInitiated CoverageBuy$42.00High
5/1/2020Northland SecuritiesReiterated RatingBuy$42.00High
11/7/2019Northland SecuritiesReiterated RatingBuy$42.00Medium
10/18/2019Northland SecuritiesReiterated RatingBuy$42.00Medium
8/2/2019Northland SecuritiesReiterated RatingBuyHigh
5/29/2019Northland SecuritiesInitiated CoverageOutperform ➝ Outperform$42.00High
10/4/2018Cantor FitzgeraldSet TargetBuy$42.00Low
9/28/2018Cantor FitzgeraldSet TargetOverweight ➝ Buy$32.00 ➝ $42.00Medium
8/28/2018Cantor FitzgeraldSet TargetBuy$32.00High
8/9/2018Cantor FitzgeraldSet TargetBuy$32.00High
7/30/2018Cantor FitzgeraldSet TargetBuy$32.00Medium
6/14/2018Cantor FitzgeraldReiterated RatingOverweightLow
6/11/2018Cantor FitzgeraldInitiated CoverageBuy$32.00High
(Data available from 12/10/2017 forward)

News Sentiment Rating

0.70 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/14/2022
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/13/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/13/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/12/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/11/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/11/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/10/2022
  • 4 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/10/2022

Current Sentiment

  • 4 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Opiant Pharmaceuticals logo
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.
Read More

Today's Range

Now: $20.21
Low: $20.15
High: $20.38

50 Day Range

MA: $14.05
Low: $9.38
High: $20.23

52 Week Range

Now: $20.21
Low: $7.34
High: $37.71

Volume

139,171 shs

Average Volume

65,104 shs

Market Capitalization

$104.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83

Frequently Asked Questions

What sell-side analysts currently cover shares of Opiant Pharmaceuticals?

The following equities research analysts have issued reports on Opiant Pharmaceuticals in the last twelve months: Cantor Fitzgerald, Northland Securities, and TheStreet.
View the latest analyst ratings for OPNT.

What is the current price target for Opiant Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Opiant Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Opiant Pharmaceuticals in the next year.
View the latest price targets for OPNT.

What is the current consensus analyst rating for Opiant Pharmaceuticals?

Opiant Pharmaceuticals currently has 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in OPNT, but not buy more shares or sell existing shares.
View the latest ratings for OPNT.

What other companies compete with Opiant Pharmaceuticals?

How do I contact Opiant Pharmaceuticals' investor relations team?

Opiant Pharmaceuticals' physical mailing address is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. The technology company's listed phone number is (310) 598-5410 and its investor relations email address is [email protected] The official website for Opiant Pharmaceuticals is www.opiant.com. Learn More about contacing Opiant Pharmaceuticals investor relations.